Connect with Us
On The Money

Our Insights

February 6, 2026

5 Things to Watch on
February 6, 2026

New TrumpRx Portal Slashes Drug Costs

Markets are rebounding today, up more than +0.5% following yesterday’s sharp selloff, with investors attempting to stabilize sentiment after a volatile week. Risk appetite improved as Bitcoin (BTC) clawed back to $67K, signaling a shaky but temporary return to risk.

Amazon Slides on $200B CapEx Fears

Amazon (AMZN) is down over -8.0% in premarket trading after the company missed earnings expectations, issued softer near-term profit guidance, and unveiled plans for roughly $200B in capital expenditures this year. While revenue beat estimates and AWS grew a strong 24% on AI-driven demand, management guided to weaker operating income in the current quarter as heavy investment spending accelerates.

Reddit Jumps on Strong Results and Buyback Announcement

Reddit (RDDT) is up over +7.0% in premarket trading after the company beat expectations and issued stronger-than-expected early-2026 guidance, pointing to accelerating growth and improving profitability. Management also announced a $1B share buyback, reinforcing confidence in cash generation, while highlighting rising user engagement and deeper AI-driven partnerships as key drivers going forward.

Strategy Rallies Despite Being Hit by Massive Bitcoin Loss

Strategy (MSTR) is up over +8.0% in premarket trading despite reporting one of the largest quarterly losses ever for a U.S. public company after a sharp bitcoin (BTC) selloff wiped out tens of billions of dollars in paper value. The firm posted an operating loss of about $17.4B, driven almost entirely by unrealized losses on its BTC holdings, as BTC fell nearly -15% in a single day. Executive Chairman Michael Saylor offered little response beyond reiterating his long-standing “HODL” stance.

FDA Crackdown Clouds Hims Outlook

Hims & Hers Health (HIMS) is down more than -7.0% in premarket trading after FDA Commissioner Marty Makary warned of swift action against companies mass-marketing “illegal copycat drugs,” a clear shot at compounded alternatives. The comments followed HIMS rolling out a discounted version of Novo Nordisk’s (NVO) new oral obesity pill, undercutting the branded price by roughly $100. NVO countered by stating it would pursue legal and regulatory action over what it called illegal compounding and deceptive advertising.